DIH Holding US (NASDAQ:DHAI) Earns “Sell (E+)” Rating from Weiss Ratings

DIH Holding US (NASDAQ:DHAI)‘s stock had its “sell (e+)” rating reissued by Weiss Ratings in a note issued to investors on Thursday,Weiss Ratings reports.

Separately, Wall Street Zen raised shares of DIH Holding US to a “sell” rating in a research report on Saturday, October 25th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

DIH Holding US Price Performance

DIH Holding US stock opened at $1.84 on Thursday. DIH Holding US has a 1-year low of $1.78 and a 1-year high of $73.25. The firm has a market capitalization of $3.85 million, a P/E ratio of -0.29 and a beta of 0.02. The company’s 50-day moving average is $4.70 and its 200 day moving average is $5.38.

DIH Holding US (NASDAQ:DHAI) last posted its quarterly earnings data on Monday, October 20th. The company reported ($1.44) earnings per share for the quarter. The company had revenue of $12.65 million for the quarter.

Hedge Funds Weigh In On DIH Holding US

A hedge fund recently bought a new stake in DIH Holding US stock. Armistice Capital LLC acquired a new stake in shares of DIH Holding US, Inc. (NASDAQ:DHAI) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 2,078,000 shares of the company’s stock, valued at approximately $481,000. Armistice Capital LLC owned approximately 4.39% of DIH Holding US as of its most recent filing with the Securities & Exchange Commission. 27.76% of the stock is currently owned by institutional investors.

About DIH Holding US

DIH Holding US, Inc operates as a robotics and virtual reality (VR) technology provider for the rehabilitation industry in Europe, the Middle East, Africa, the United States, and the Asia Pacific. It offers ArmeoPower, a backbone robot for arm and hand therapy in an early stage of rehabilitation; ArmeoSpring for less severe patients that provides self-initiated repetitive arm and hand therapy in an extensive workspace; ArmeoSpring Pro; and Armeo Senso, for patients self-initiated and still structurally controlled movement patterns to completely open movement.